Latest One Wales decisions
- 13/03/2026
- Nivolumab plus ipilimumab for stage III melanoma (OW35)
-
-
-
Issue date: March 2026
- 02/02/2023
- Infliximab for the treatment of ICI induced enterocolitis (OW21)
-
-
-
Last review date: March 2026
- 02/02/2023
- Vedolizumab (Entyvio®) for the treatment of ICI induced enterocolitis (OW22)
-
-
-
Last review date: March 2026
- 13/02/2026
- Infliximab for the treatment of ICI induced pneumonitis (OW34)
-
-
-
Issue date: February 2026
- 26/07/2021
- Azacitidine for progressive angioimmunoblastic T-cell lymphoma (OW16)
-
-
-
Last review date: February 2026
- 09/12/2025
- Venetoclax with azacitidine for relapsed/refractory acute myeloid leukaemia (OW32)
-
-
-
Issue date: December 2025
- 26/04/2023
- Rituximab for myasthenia gravis (OW12)
-
-
-
Last review date: December 2025
- 01/05/2024
- Dabrafenib and trametinib for anaplastic thyroid cancer (OW27)
-
-
-
Last review date: October 2025
- 14/10/2025
- Nivolumab for oesophageal and gastric cancer (OW28)
-
-
-
Last review date: October 2025
- 12/09/2025
- Infliximab for the treatment of ICI induced myocarditis (OW31)
-
-
-
Issue date: September 2025
- 20/06/2025
- Trametinib (Mekinist®) for recurrent low grade serous ovarian carcinoma (OW30)
-
-
-
Issue date: June 2025
- 20/06/2025
- Panitumumab (Vectibix®) rechallenge for metastatic colorectal cancer (OW29)
-
-
-
Issue date: June 2025
- 13/02/2025
- Vonicog alfa (Veyvondi®) for on-demand treatment of bleeding episodes in children with von Willebrand Disease (OW19)
-
-
-
Last review date: December 2024
- 04/09/2023
- Dostarlimab (Jemperli®) for locally advanced rectal cancer (OW26)
-
-
-
Last review date: October 2024
- 08/03/2023
- Ustekinumab (Stelara®) for the treatment of inflammatory bowel disease in children (OW25)
-
-
-
Last review date: May 2024
- 08/03/2023
- Vedolizumab (Entyvio®) for the treatment of inflammatory bowel disease in children (OW24)
-
-
-
Last review date: May 2024
- 08/03/2023
- Infliximab for the treatment of refractory pulmonary sarcoidosis (OW23)
-
-
-
Last review date: May 2024
- 01/05/2024
- Abiraterone for non-metastatic and locally advanced, high-risk, hormone-sensitive prostate cancer (OW20)
-
-
-
Last review date: April 2024
- 14/02/2024
- Bevacizumab for ovarian cancer (OW01)
-
-
-
Last review date: February 2024
- 14/02/2024
- Bendamustine and rituximab for mantle cell lymphoma (OW09)
-
-
-
Last review date: February 2024